<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37265584</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Biological mechanisms underpinning the development of long COVID.</ArticleTitle><Pagination><StartPage>106935</StartPage><MedlinePgn>106935</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">106935</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2023.106935</ELocationID><Abstract><AbstractText>As COVID-19 evolves from a pandemic to an endemic disease, the already staggering number of people that have been or will be infected with SARS-CoV-2 is only destined to increase, and the majority of humanity will be infected. It is well understood that COVID-19, like many other viral infections, leaves a significant fraction of the infected with prolonged consequences. Continued high number of SARS-CoV-2 infections, viral evolution with escape from post-infection and vaccinal immunity, and reinfections heighten the potential impact of Long COVID. Hence, the impact of COVID-19 on human health will be seen for years to come until more effective vaccines and pharmaceutical treatments become available. To that effect, it is imperative that the mechanisms underlying the clinical manifestations of Long COVID be elucidated. In this article, we provide an in-depth analysis of the evidence on several potential mechanisms of Long COVID and discuss their relevance to its pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perumal</LastName><ForeName>Rubeshan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>South African Medical Research Council (SAMRC)-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban 4001, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pulmonology and Critical Care, Division of Internal Medicine, School of Clinical Medicine, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban 4001, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunobiology and the University of Arizona Center on Aging, University of Arizona College of Medicine-Tucson, Tucson, AZ 85724, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shunmugam</LastName><ForeName>Letitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>South African Medical Research Council (SAMRC)-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban 4001, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidoo</LastName><ForeName>Kogieleum</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>South African Medical Research Council (SAMRC)-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban 4001, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Dave</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Global Virus Network, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzino-Demo</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Global Virus Network, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Padova, Padova 1- 35129, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brechot</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Global Virus Network, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease and International Health, University of South Florida, Tampa, FL 33620, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahlne</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Global Virus Network, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Microbiology, Karolinska Institute, Stockholm 17165, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nikolich</LastName><ForeName>Janko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Global Virus Network, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Aegis Consortium for Pandemic-Free Future, University of Arizona Health Sciences, University of Arizona College of Medicine-Tucson, Tucson, AZ 85724, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_16022</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Health sciences</Keyword><Keyword MajorTopicYN="N">Medicine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>13</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>13</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37265584</ArticleId><ArticleId IdType="pmc">PMC10193768</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2023.106935</ArticleId><ArticleId IdType="pii">S2589-0042(23)01012-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Estrada L.v., Levasseur J.L., Maxim A., Benavidez G.A., Porter K.M.P. Structural racism, place, and COVID-19: a narrative review describing how we prepare for an endemic COVID-19 future. Health Equity. 2022;6:356&#x2013;366. doi: 10.1089/HEQ.2021.0190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/HEQ.2021.0190</ArticleId><ArticleId IdType="pmc">PMC9148659</ArticleId><ArticleId IdType="pubmed">35651360</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabore J.W., Karamagi H.C., Kipruto H.K., Mungatu J.K., Asamani J.A., Droti B., Titi-ofei R., Seydi A.B.W., Kidane S.N., Balde T., et al. COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past trends and future patterns. Lancet Glob Health. 2022;10:e1099. doi: 10.1016/S2214-109X(22)00233-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00233-9</ArticleId><ArticleId IdType="pmc">PMC9159735</ArticleId><ArticleId IdType="pubmed">35659911</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese H., Iuliano A.D., Patel N.N., Garg S., Kim L., Silk B.J., Hall A.J., Fry A., Reed C. Estimated incidence of coronavirus disease 2019 (COVID-19) illness and hospitalization&#x2014;United States, February&#x2013;September 2020. Clin. Infect. Dis. 2021;72:e1010&#x2013;e1017. doi: 10.1093/CID/CIAA1780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAA1780</ArticleId><ArticleId IdType="pmc">PMC7717219</ArticleId><ArticleId IdType="pubmed">33237993</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I., Fonseca-Rodr&#xed;guez O., Farrington P., Jerndal H., Lundevaller E.H., Sund M., Lindmark K., Fors Connolly A.M. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377 doi: 10.1136/BMJ-2021-069590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ-2021-069590</ArticleId><ArticleId IdType="pmc">PMC8984137</ArticleId><ArticleId IdType="pubmed">35387772</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Original research: multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11 doi: 10.1136/BMJOPEN-2020-048391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJOPEN-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran K., Rentsch C.T., Hickman G., Hulme W.J., Schultze A., Curtis H.J., Wing K., Warren-Gash C., Tomlinson L., Bates C.J., et al. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: a cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLoS Med. 2022;19:e1003871. doi: 10.1371/JOURNAL.PMED.1003871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PMED.1003871</ArticleId><ArticleId IdType="pmc">PMC8789178</ArticleId><ArticleId IdType="pubmed">35077449</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca-Fernandez A., Wamil M., Telford A., Carapella V., Borlotti A., Monteiro D., Thomaides-Brears H., Dennis A., Banerjee R., Robson M.D., et al. Cardiac impairment in Long Covid 1-year post SARS-CoV-2 infection. Eur. Heart J. 2022;43 doi: 10.1093/EURHEARTJ/EHAC544. ehac544.219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURHEARTJ/EHAC544</ArticleId><ArticleId IdType="pmc">PMC9950586</ArticleId><ArticleId IdType="pubmed">36822818</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A., Kudryavtsev I., Starshinova A., Kudlay D., Zinchenko Y., Glushkova A., Yablonskiy P., Shoenfeld Y. Post COVID-19 syndrome in patients with asymptomatic/mild form. Pathogens. 2021;10:1408. doi: 10.3390/PATHOGENS10111408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/PATHOGENS10111408</ArticleId><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanga V., Chevinsky J.R., Dimitrov L.v., Gerdes M.E., Whitfield G.P., Bonacci R.A., Nji M.A.M., Hernandez-Romieu A.C., Rogers-Brown J.S., McLeod T., et al. Long-term symptoms among adults tested for SARS-CoV-2 &#x2014; United States, January 2020&#x2013;April 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1235&#x2013;1241. doi: 10.15585/MMWR.MM7036A1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/MMWR.MM7036A1</ArticleId><ArticleId IdType="pmc">PMC8437054</ArticleId><ArticleId IdType="pubmed">34499626</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E., Ba D.M., Parsons N., Poudel G.R., Lekoubou A., Oh J.S., Ericson J.E., Ssentongo P., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open. 2021;4 doi: 10.1001/JAMANETWORKOPEN.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMANETWORKOPEN.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., Wang Q., Ren L., Wang Y., Hu P., Guo L., Liu M., Xu J., et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/BMJ.N693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ.N693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Pawelek P., Gaughan C. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK - office for National Statistics. 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021</Citation></Reference><Reference><Citation>Ballering A.v., van Zon S.K.R., olde Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Morrone M.C., Patrono C., Santoro M.G., Schiaffino S., Remuzzi G., Bussolati G., Cappuccinelli P., Fitzgerald G., Bacci M.L., et al. Long Covid: where we stand and challenges ahead. Cell Death Differ. 2022;29:1891. doi: 10.1038/S41418-022-01052-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41418-022-01052-6</ArticleId><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffieux H., Hanson A.L., Lodge S., Lawler N.G., Whiley L., Gray N., Nolan T.H., Bergamaschi L., Mescia F., Turner L., et al. A patient-centric modeling framework captures recovery from SARS-CoV-2 infection. Nat. Immunol. 2023;24:349. doi: 10.1038/S41590-022-01380-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41590-022-01380-2</ArticleId><ArticleId IdType="pmc">PMC9892000</ArticleId><ArticleId IdType="pubmed">36717723</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601. doi: 10.1038/S41591-021-01283-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41591-021-01283-Z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.H., Koepke L., Kirchhoff F., Sparrer K.M.J. Interferon antagonists encoded by SARS-CoV-2 at a glance. Med. Microbiol. Immunol. 2022;212:125&#x2013;131. doi: 10.1007/S00430-022-00734-9/FIGURES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00430-022-00734-9/FIGURES/1</ArticleId><ArticleId IdType="pmc">PMC8976456</ArticleId><ArticleId IdType="pubmed">35366686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokugamage K.G., Hage A., de Vries M., Valero-Jimenez A.M., Schindewolf C., Dittmann M., Rajsbaum R., Menachery V.D. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J.&#xa0;Virol. 2020;94:e01410-20. doi: 10.1128/JVI.01410-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01410-20</ArticleId><ArticleId IdType="pmc">PMC7654262</ArticleId><ArticleId IdType="pubmed">32938761</ArticleId></ArticleIdList></Reference><Reference><Citation>Essaidi-Laziosi M., Alvarez C., Puhach O., Sattonnet-Roche P., Torriani G., Tapparel C., Kaiser L., Eckerle I. Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract. Emerg. Microb. Infect. 2022;11:412&#x2013;423. doi: 10.1080/22221751.2021.2021806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2021806</ArticleId><ArticleId IdType="pmc">PMC8803056</ArticleId><ArticleId IdType="pubmed">34931581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Zhang Q., Zhang S.Y., Jouanguy E., Casanova J.L. Type I interferons and SARS-CoV-2: from cells to organisms. Curr. Opin. Immunol. 2022;74:172&#x2013;182. doi: 10.1016/J.COI.2022.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.COI.2022.01.003</ArticleId><ArticleId IdType="pmc">PMC8786610</ArticleId><ArticleId IdType="pubmed">35149239</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani I.E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E., Koukaki E., Fragkou P.C., Panou V., Rapti V., et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 2021;22:32&#x2013;40. doi: 10.1038/S41590-020-00840-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41590-020-00840-X</ArticleId><ArticleId IdType="pubmed">33277638</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbraith M.D., Kinning K.T., Sullivan K.D., Araya P., Smith K.P., Granrath R.E., Shaw J.R., Baxter R., Jordan K.R., Russell S., et al. Specialized interferon action in COVID-19. Proc. Natl. Acad. Sci. USA. 2022;119 doi: 10.1073/PNAS.2116730119. e2116730119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2116730119</ArticleId><ArticleId IdType="pmc">PMC8931386</ArticleId><ArticleId IdType="pubmed">35217532</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P., Casari G., Townsend L., O&#x2019;Farrelly C., Tancevski I., L&#xf6;ffler-Ragg J., Mogensen T.H., Casanova J.L., Abel L., Aiuti A., et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat. Med. 2022;28:879&#x2013;882. doi: 10.1038/s41591-022-01766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01766-7</ArticleId><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuga Y., Zhu B., Jang K.J., Yoo J.S. Innate immune sensing of coronavirus and viral evasion strategies. Exp. Mol. Med. 2021;53:723&#x2013;736. doi: 10.1038/s12276-021-00602-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00602-1</ArticleId><ArticleId IdType="pmc">PMC8099713</ArticleId><ArticleId IdType="pubmed">33953325</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:1494. doi: 10.3389/FMICB.2021.698169/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMICB.2021.698169/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deveau T.-M., Munter S.E., Ryder D., Buck A., Beck-Engeser G., Chan F., Lu S., Goldberg S.A., Hoh R., et al. Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. medRxiv. 2022 doi: 10.1101/2022.06.21.22276660. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276660</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A., Koch R., Jukic A., Pfister A., Meyer M., R&#xf6;ssler A., Kimpel J., Adolph T.E., Tilg H. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495&#x2013;506.e8. doi: 10.1053/J.GASTRO.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/J.GASTRO.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Desimmie B.A., Raru Y.Y., Awadh H.M., He P., Teka S., Willenburg K.S. Insights into SARS-CoV-2 persistence and its relevance. Viruses. 2021;13:1025. doi: 10.3390/V13061025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/V13061025</ArticleId><ArticleId IdType="pmc">PMC8228265</ArticleId><ArticleId IdType="pubmed">34072390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar-Rodr&#xed;guez A., Padilla-Gonz&#xe1;lez A., Rivera-Toledo E. Coronavirus persistence in human respiratory tract and cell culture: an overview. Braz. J. Infect. Dis. 2021;25 doi: 10.1016/J.BJID.2021.101632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BJID.2021.101632</ArticleId><ArticleId IdType="pmc">PMC8486621</ArticleId><ArticleId IdType="pubmed">34627782</ArticleId></ArticleIdList></Reference><Reference><Citation>Caniego-Casas T., Mart&#xed;nez-Garc&#xed;a L., Alonso-Ria&#xf1;o M., Pizarro D., Carretero-Barrio I., Mart&#xed;nez-de-Castro N., Ruz-Caracuel I., de Pablo R., Saiz A., Royo R.N., et al. RNA SARS-CoV-2 persistence in the lung of severe COVID-19 patients: a case series of autopsies. Front. Microbiol. 2022;13:1. doi: 10.3389/FMICB.2022.824967/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FMICB.2022.824967/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8841799</ArticleId><ArticleId IdType="pubmed">35173701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn T., Mhedhbi I., Hein S., Raupach J., Miskey C., Husria Y., Bayanga K., Bartel D., Vieths S., Ivics Z., et al. Persistence of infectious SARS-CoV-2 particles for up to 37&#xa0;days in patients with mild COVID-19. Allergy. 2021;77:2053&#x2013;2066. doi: 10.1111/ALL.15138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ALL.15138</ArticleId><ArticleId IdType="pmc">PMC8652783</ArticleId><ArticleId IdType="pubmed">34637150</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Green J., Santillana M., Lazer D., Ognyanova K., Simonson M., Baum M.A., Quintana A., Chwe H., Druckman J., et al. Persistence of symptoms up to 10&#xa0;months following acute COVID-19 illness. medRxiv. 2021 doi: 10.1101/2021.03.07.21253072. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.07.21253072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C.W., Sun J., Dickey J.M., Ylaya K., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763. doi: 10.1038/S41586-022-05542-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-022-05542-Y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong T.T., Ryutov A., Pandey U., Yee R., Goldberg L., Bhojwani D., Aguayo-Hiraldo P., Pinsky B.A., Pekosz A., Shen L., et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series. EBioMedicine. 2021;67:103355. doi: 10.1016/J.EBIOM.2021.103355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EBIOM.2021.103355</ArticleId><ArticleId IdType="pmc">PMC8072072</ArticleId><ArticleId IdType="pubmed">33915337</ArticleId></ArticleIdList></Reference><Reference><Citation>Maponga T.G., Jeffries M., Tegally H., Sutherland A., Wilkinson E., Lessells R.J., Msomi N., Zyl G. van, Oliveira T. de, Preiser W. Persistent SARS-CoV-2 infection with accumulation of mutations in a patient with poorly controlled HIV infection. Clin. Infect. Dis. 2022 doi: 10.1093/CID/CIAC548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAC548</ArticleId><ArticleId IdType="pmc">PMC9278209</ArticleId><ArticleId IdType="pubmed">35793242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. Where did &#x201c;weird&#x201d; Omicron come from? Science. 2021;374:1179. doi: 10.1126/SCIENCE.ACX9738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ACX9738</ArticleId><ArticleId IdType="pubmed">34855502</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., Anyaneji U.J., Bester P.A., Boni M.F., Chand M., et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603:679&#x2013;686. doi: 10.1038/S41586-022-04411-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-022-04411-Y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M.H., Zhang S., Porritt R.A., Rivas M.N., Paschold L., Willscher E., Binder M., Arditi M., Bahar I. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc. Natl. Acad. Sci. USA. 2020;117:25254&#x2013;25262. doi: 10.1073/PNAS.2010722117/-/DCSUPPLEMENTAL.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/PNAS.2010722117/-/DCSUPPLEMENTAL</ArticleId><ArticleId IdType="pmc">PMC7568239</ArticleId><ArticleId IdType="pubmed">32989130</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul T., Ledderose S., Bartsch H., Sun N., Soliman S., M&#xe4;rkl B., Ruf V., Herms J., Stern M., Keppler O.T., et al. Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19. Nat. Commun. 2022;13:1&#x2013;12. doi: 10.1038/s41467-022-29145-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29145-3</ArticleId><ArticleId IdType="pmc">PMC8948269</ArticleId><ArticleId IdType="pubmed">35332140</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Hu J., Liu L., Chen R., Wang M., Xiong M., Li Z.Q., Zhao Y., Li H., Guan C., et al. SARS-CoV-2 causes acute kidney injury by directly infecting renal tubules. Front. Cell Dev. Biol. 2021;9:1245. doi: 10.3389/FCELL.2021.664868/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCELL.2021.664868/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8201778</ArticleId><ArticleId IdType="pubmed">34136484</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Q., Fan L., Liu W., Li J., Yue J., Wang M., Ke X., Yin Y., Chen Q., Jiang C. Direct evidence of active SARS-CoV-2 replication in the intestine. Clin. Infect. Dis. 2021;73:361&#x2013;366. doi: 10.1093/CID/CIAA925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAA925</ArticleId><ArticleId IdType="pmc">PMC7454471</ArticleId><ArticleId IdType="pubmed">32638022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bostanc&#x131;kl&#x131;o&#x11f;lu M. SARS-CoV2 entry and spread in the lymphatic drainage system of the brain. Brain Behav. Immun. 2020;87:122. doi: 10.1016/J.BBI.2020.04.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BBI.2020.04.080</ArticleId><ArticleId IdType="pmc">PMC7189839</ArticleId><ArticleId IdType="pubmed">32360606</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Q., Feng Z., Diao B., Tu C., Qiao Q., Yang H., Zhang Y., Wang G., Wang H., Wang C., et al. SARS-CoV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs. Front. Immunol. 2021;12:1292. doi: 10.3389/FIMMU.2021.661052/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.661052/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC8113960</ArticleId><ArticleId IdType="pubmed">33995382</ArticleId></ArticleIdList></Reference><Reference><Citation>Escher F., Pietsch H., Aleshcheva G., Bock T., Baumeier C., Elsaesser A., Wenzel P., Hamm C., Westenfeld R., Schultheiss M., et al. Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies. ESC Heart Fail. 2020;7:2440&#x2013;2447. doi: 10.1002/EHF2.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/EHF2.12805</ArticleId><ArticleId IdType="pmc">PMC7307078</ArticleId><ArticleId IdType="pubmed">32529795</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., Tate M., Lloyd O., Maraolo A.E., Schafers J., Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2:e13&#x2013;e22. doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N., Wang X., Lv T. Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J.&#xa0;Med. Virol. 2020;92:2286&#x2013;2287. doi: 10.1002/JMV.25952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JMV.25952</ArticleId><ArticleId IdType="pmc">PMC7267144</ArticleId><ArticleId IdType="pubmed">32347980</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F., Catalan P., Rodriguez-Grande C., Adan J., Rodriguez-Gonzalez C., Mu&#xf1;oz P., Aldamiz T., Diez C., Perez L., Fanciulli C., et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect. Dis. 2022;22 doi: 10.1186/S12879-022-07153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Zhang Z., Jin L., Chu F., Mao Y., Wang H., Liu M., Wang M., Zhang L., Gao G.F., et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur. J. Clin. Microbiol. Infect. Dis. 2005;24:165. doi: 10.1007/S10096-005-1299-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10096-005-1299-5</ArticleId><ArticleId IdType="pmc">PMC7088045</ArticleId><ArticleId IdType="pubmed">15789222</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F., Sun J., Xu Y., Li F., Huang X., Li H., Zhao J., Huang J., Zhao J. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg. Infect. Dis. 2020;26:1920. doi: 10.3201/EID2608.200681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/EID2608.200681</ArticleId><ArticleId IdType="pmc">PMC7392466</ArticleId><ArticleId IdType="pubmed">32421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen C., Zhu S., Shu C., Wang D., Song J., Song Y., Zhen W., Feng Z., Wu G., et al. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19) China CDC Wkly. 2020;2:123&#x2013;124. doi: 10.46234/CCDCW2020.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/CCDCW2020.033</ArticleId><ArticleId IdType="pmc">PMC8392928</ArticleId><ArticleId IdType="pubmed">34594837</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H.W., Kim S.M., Kim H.S., Kim Y.I., Kim J.H., Cho J.Y., Kim S.H., Kang H., Kim S.G., Park S.J., et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clin. Microbiol. Infection. 2020;26:1520&#x2013;1524. doi: 10.1016/J.CMI.2020.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2020.07.020</ArticleId><ArticleId IdType="pmc">PMC7375961</ArticleId><ArticleId IdType="pubmed">32711057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Xu Y., Gao R., Lu R., Han K., Wu G., Tan W. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843&#x2013;1844. doi: 10.1001/JAMA.2020.3786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.3786</ArticleId><ArticleId IdType="pmc">PMC7066521</ArticleId><ArticleId IdType="pubmed">32159775</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerrada-Romero C., Berastegui-Cabrera J., Camacho-Mart&#xed;nez P., Goikoetxea-Aguirre J., P&#xe9;rez-Palacios P., Santib&#xe1;&#xf1;ez S., Jos&#xe9; Blanco-Vidal M., Valiente A., Alba J., Rodr&#xed;guez-&#xc1;lvarez R., et al. Excretion and viability of SARS-CoV-2 in feces and its association with the clinical outcome of COVID-19. Sci. Rep. 2022;12:7397. doi: 10.1038/s41598-022-11439-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11439-7</ArticleId><ArticleId IdType="pmc">PMC9070969</ArticleId><ArticleId IdType="pubmed">35513481</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Zlitni S., Brooks E.F., Vance S.E., Dahlen A., Hedlin H., Park R.M., Han A., Schmidtke D.T., Verma R., et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371. doi: 10.1016/J.MEDJ.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MEDJ.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M., Tao W., Flavell R.A., Zhu S. Potential intestinal infection and faecal-oral transmission of SARS-CoV-2. Nat. Rev. Gastroenterol. Hepatol. 2021;18:269&#x2013;283. doi: 10.1038/S41575-021-00416-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41575-021-00416-6</ArticleId><ArticleId IdType="pmc">PMC7883337</ArticleId><ArticleId IdType="pubmed">33589829</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung C.C.L., Goh D., Lim X., Tien T.Z., Lim J.C.T., Lee J.N., Tan B., Tay Z.E.A., Wan W.Y., Chen E.X., et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71:226&#x2013;229. doi: 10.1136/gutjnl-2021-324570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324570</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Hu Y., Yuanyuan Y., Zhang X., Xiaodong Z., Bin L., Wu J., Li J., Wu Y., Xia X., et al. Positive result of Sars-Cov-2 in faeces and sputum from discharged patients with COVID-19 in Yiwu, China. J.&#xa0;Med. Virol. 2020;92:1938&#x2013;1947. doi: 10.1002/jmv.25905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25905</ArticleId><ArticleId IdType="pmc">PMC7264799</ArticleId><ArticleId IdType="pubmed">32311109</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Liu Q., Zhang F., Chung-Yan Lui G., Tso E.Y., Kit Yeoh Y., Chen Z., Shi Boon S., Chan F.K., Chan P.K., et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70:276&#x2013;284. doi: 10.1136/gutjnl-2020-322294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322294</ArticleId><ArticleId IdType="pmc">PMC7385744</ArticleId><ArticleId IdType="pubmed">32690600</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan B., Liu H.Q., Yang Z.R., Chen Y.X., Liu Z.Y., Zhang K., Wang C., Li W.X., An Y.W., Wang J.C., et al. Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation. Sci. Rep. 2020;10:1&#x2013;7. doi: 10.1038/s41598-020-68782-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-68782-w</ArticleId><ArticleId IdType="pmc">PMC7368008</ArticleId><ArticleId IdType="pubmed">32681141</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Francisco E.B., Yogendra R., Long E., Pise A., Rodrigues H., Hall E., Herrera M., Parikh P., Guevara-Coto J., et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 Months post-infection. Front. Immunol. 2022;12:746021. doi: 10.3389/FIMMU.2021.746021/FULL.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.746021/FULL</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., Senussi Y., Manickas-Hill Z., Yu X.G., Li J.Z., Alter G., Walt D.R. Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin. Infect. Dis. 2023;76:e487&#x2013;e490. doi: 10.1093/CID/CIAC722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAC722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.v., Misra A. Post COVID-19 syndrome (&#x201c;Long COVID&#x201d;) and diabetes: challenges in diagnosis and management. Diabetes Metabol. Syndr. 2021;15 doi: 10.1016/J.DSX.2021.102235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DSX.2021.102235</ArticleId><ArticleId IdType="pmc">PMC8317446</ArticleId><ArticleId IdType="pubmed">34384972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagman K., Hedenstierna M., Rudling J., Gille-Johnson P., Hammas B., Grabbe M., Jakobsson J., Dillner J., Ursing J. Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study. Diagn. Microbiol. Infect. Dis. 2022;102 doi: 10.1016/J.DIAGMICROBIO.2021.115595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.DIAGMICROBIO.2021.115595</ArticleId><ArticleId IdType="pmc">PMC8595972</ArticleId><ArticleId IdType="pubmed">34896666</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Schneider A.M., Mehta A., Sade-Feldman M., Kays K.R., Gentili M., Charland N.C., Gonye A.L.K., Gushterova I., Khanna H.K., et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J.&#xa0;Clin. Invest. 2021;131:e148635. doi: 10.1172/JCI148635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148635</ArticleId><ArticleId IdType="pmc">PMC8245177</ArticleId><ArticleId IdType="pubmed">34196300</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Ramonell R.P., Nguyen D.C., Cashman K.S., Saini A.S., Haddad N.S., Ley A.M., Kyu S., Howell J.C., Ozturk T., et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 2020;21:1506&#x2013;1516. doi: 10.1038/S41590-020-00814-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41590-020-00814-Z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Basic-Jukic N., Juric I., Furic-Cunko V., Katalinic L., Radic J., Bosnjak Z., Jelakovic B., Kastelan Z. Follow-up of renal transplant recipients after acute COVID-19&#x2014;a prospective cohort single-center study. Immun Inflamm Dis. 2021;9:1563&#x2013;1572. doi: 10.1002/IID3.509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/IID3.509</ArticleId><ArticleId IdType="pmc">PMC8426882</ArticleId><ArticleId IdType="pubmed">34414665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of long COVID prevalence and its relationship to Epstein-barr virus reactivation. Pathogens. 2021;10 doi: 10.3390/PATHOGENS10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/PATHOGENS10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. doi: 10.1016/J.CELL.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CELL.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deveau T.-M., Munter S.E., Ryder D.M., Buck A.M., Beck-Engeser G., Chan F., Lu S., Goldberg S.A., Hoh R., et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J.&#xa0;Clin. Invest. 2023;133:e163669. doi: 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Danwang C., Noubiap J.J., Robert A., Yombi J.C. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res. Ther. 2022;19:1&#x2013;12. doi: 10.1186/S12981-021-00427-Y/FIGURES/4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12981-021-00427-Y/FIGURES/4</ArticleId><ArticleId IdType="pmc">PMC8759058</ArticleId><ArticleId IdType="pubmed">35031068</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Iwasaki A. Impact of chronic HIV infection on SARS-CoV-2 infection, COVID-19 disease and vaccines. Curr. HIV AIDS Rep. 2022;19:5&#x2013;16. doi: 10.1007/S11904-021-00590-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11904-021-00590-X</ArticleId><ArticleId IdType="pmc">PMC8628277</ArticleId><ArticleId IdType="pubmed">34843064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujari S., Gaikwad S., Chitalikar A., Dabhade D., Joshi K., Bele V. Long-coronavirus disease among people living with HIV in western India: an observational study. Immun Inflamm Dis. 2021;9:1037&#x2013;1043. doi: 10.1002/IID3.467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/IID3.467</ArticleId><ArticleId IdType="pmc">PMC8239760</ArticleId><ArticleId IdType="pubmed">34078004</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Spinelli M.A., Deveau T.M., Forman C.A., Munter S.E., Mathur S., Tang A.F., Lu S., Goldberg S.A., Arreguin M.I., et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS. 2022;36:F7&#x2013;F16. doi: 10.1097/QAD.0000000000003338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003338</ArticleId><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference><Reference><Citation>Altuntas Aydin O., Kumbasar Karaosmanoglu H., Kart Yasar K. HIV/SARS-CoV-2 coinfected patients in Istanbul, Turkey. J.&#xa0;Med. Virol. 2020;92:2288&#x2013;2290. doi: 10.1002/JMV.25955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JMV.25955</ArticleId><ArticleId IdType="pubmed">32347975</ArticleId></ArticleIdList></Reference><Reference><Citation>del Amo J., Polo R., Moreno S., D&#xed;az A., Mart&#xed;nez E., Arribas J.R., Jarr&#xed;n I., Hern&#xe1;n M.A. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy : a cohort study. Ann. Intern. Med. 2020;173:536&#x2013;541. doi: 10.7326/M20-3689.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-3689</ArticleId><ArticleId IdType="pmc">PMC7394316</ArticleId><ArticleId IdType="pubmed">32589451</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N.&#xa0;Engl. J. Med. 2020;382:1787&#x2013;1799. doi: 10.1056/NEJMOA2001282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMOA2001282</ArticleId><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt P.W., Martin J.N., Sinclair E., Bredt B., Hagos E., Lampiris H., Deeks S.G. T cell activation is associated with lower CD4+ T&#xa0;cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J.&#xa0;Infect. Dis. 2003;187:1534&#x2013;1543. doi: 10.1086/374786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/374786</ArticleId><ArticleId IdType="pubmed">12721933</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrubayyi A., Gea-Mallorqu&#xed; E., Touizer E., Hameiri-Bowen D., Kopycinski J., Charlton B., Fisher-Pearson N., Muir L., Rosa A., Roustan C., et al. Characterization of humoral and SARS-CoV-2 specific T&#xa0;cell responses in people living with HIV. Nat. Commun. 2021;12:1&#x2013;16. doi: 10.1038/s41467-021-26137-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26137-7</ArticleId><ArticleId IdType="pmc">PMC8492866</ArticleId><ArticleId IdType="pubmed">34611163</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S., Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Br&#xfc;ggen M.C., O&#x2019;Mahony L., Gao Y., Nadeau K., Akdis C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564&#x2013;1581. doi: 10.1111/ALL.14364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ALL.14364</ArticleId><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J.J.L. Persistent SARS-2 infections contribute to long COVID-19. Med. Hypotheses. 2021;149 doi: 10.1016/J.MEHY.2021.110538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MEHY.2021.110538</ArticleId><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., Kell D.B. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20 doi: 10.1186/S12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid Y., Puhm F., Allaeys I., Naya A., Oudghiri M., Khalki L., Limami Y., Zaid N., Sadki K., ben El Haj R., et al. Platelets can associate with SARS-CoV-2 RNA and are hyperactivated in COVID-19. Circ. Res. 2020;127:1404. doi: 10.1161/CIRCRESAHA.120.317703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317703</ArticleId><ArticleId IdType="pmc">PMC7641188</ArticleId><ArticleId IdType="pubmed">32938299</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D. Targeting SARS-CoV-2-platelet interactions in COVID-19 and vaccine-related thrombosis. Front. Pharmacol. 2021;12:708665. doi: 10.3389/FPHAR.2021.708665.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FPHAR.2021.708665</ArticleId><ArticleId IdType="pmc">PMC8287727</ArticleId><ArticleId IdType="pubmed">34290613</ArticleId></ArticleIdList></Reference><Reference><Citation>Koupenova M., Kehrel B.E., Corkrey H.A., Freedman J.E. Thrombosis and platelets: an update. Eur. Heart J. 2017;38:785&#x2013;791. doi: 10.1093/EURHEARTJ/EHW550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURHEARTJ/EHW550</ArticleId><ArticleId IdType="pmc">PMC11110018</ArticleId><ArticleId IdType="pubmed">28039338</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell W.B. Reference Module in Biomedical Sciences. 2014. Platelets.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-801238-3.00062-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M., Ngoepe M., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B., Pretorius E. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci. Rep. 2021;41 doi: 10.1042/BSR20210611/229418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210611/229418</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Narayan R.K., Kumari C., Faiq M.A., Kulandhasamy M., Kant K., Pareek V. SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in COVID-19 patients. Med. Hypotheses. 2020;145 doi: 10.1016/J.MEHY.2020.110320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.MEHY.2020.110320</ArticleId><ArticleId IdType="pmc">PMC7525265</ArticleId><ArticleId IdType="pubmed">33032170</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Liu Y., Wang X., Yang L., Li H., Wang Y., Liu M., Zhao X., Xie Y., Yang Y., et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J.&#xa0;Hematol. Oncol. 2020;13:1&#x2013;22. doi: 10.1186/S13045-020-00954-7/FIGURES/8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13045-020-00954-7/FIGURES/8</ArticleId><ArticleId IdType="pmc">PMC7471641</ArticleId><ArticleId IdType="pubmed">32887634</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G.J., Kotze M.J., Oladejo S.O., Watson L.R., Rajaratnam K., Watson B.W., Kell D.B. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) Cardiovasc. Diabetol. 2022;21:1&#x2013;17. doi: 10.1186/S12933-022-01579-5/FIGURES/12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12933-022-01579-5/FIGURES/12</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Da R., Gorman S., Syed I.U. Connecting the dots in emerging mast cell research: do factors affecting mast cell activation provide a missing link between adverse COVID-19 outcomes and the social determinants of health? Med. Sci. 2022;10:29. doi: 10.3390/MEDSCI10020029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/MEDSCI10020029</ArticleId><ArticleId IdType="pmc">PMC9228930</ArticleId><ArticleId IdType="pubmed">35736349</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock L.B., Brook J.B., Walters A.S., Goris A., Afrin L.B., Molderings G.J. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis. 2021;112:217. doi: 10.1016/J.IJID.2021.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IJID.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327. doi: 10.1016/J.IJID.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IJID.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita H., Saito H., Matsumoto K., Nakae S. Regulatory roles of mast cells in immune responses. Semin. Immunopathol. 2016;38:623&#x2013;629. doi: 10.1007/S00281-016-0566-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00281-016-0566-0</ArticleId><ArticleId IdType="pubmed">27154294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., Anderson D.E., Rathore A.P.S., O&#x2019;Neill A., Mantri C.K., Saron W.A.A., Lee C., Cui C.W., Kang A.E.Z., Foo R., et al. Signatures of mast cell activation are associated with severe COVID-19. medRxiv. 2021 doi: 10.1101/2021.05.31.21255594. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.31.21255594</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Potential association of mast cells with coronavirus disease 2019. Ann. Allergy Asthma Immunol. 2021;126:217&#x2013;218. doi: 10.1016/J.ANAI.2020.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ANAI.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7644430</ArticleId><ArticleId IdType="pubmed">33161155</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Conti P. Covid-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J.&#xa0;Biol. Regul. Homeost. Agents. 2020;34:1633&#x2013;1636. doi: 10.23812/20-EDIT3.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-EDIT3</ArticleId><ArticleId IdType="pubmed">33023287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritas S.K., Ronconi G., Caraffa A., Gallenga C.E., Ross R., Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J.&#xa0;Biol. Regul. Homeost. Agents. 2020;34:9&#x2013;14. doi: 10.23812/20-EDITORIAL-KRITAS.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-EDITORIAL-KRITAS</ArticleId><ArticleId IdType="pubmed">32013309</ArticleId></ArticleIdList></Reference><Reference><Citation>Atiakshin D., Buchwalow I., Tiemann M. Mast cells and collagen fibrillogenesis. Histochem. Cell Biol. 2020;154:21&#x2013;40. doi: 10.1007/S00418-020-01875-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00418-020-01875-9</ArticleId><ArticleId IdType="pubmed">32222902</ArticleId></ArticleIdList></Reference><Reference><Citation>Raha A.A., Chakraborty S., Henderson J., Mukaetova-Ladinska E., Zaman S., Trowsdale J., Raha-Chowdhury R. Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology. Biosci. Rep. 2020;40 doi: 10.1042/BSR20203092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20203092</ArticleId><ArticleId IdType="pmc">PMC7693198</ArticleId><ArticleId IdType="pubmed">33205807</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Zhang W., Li T., Yang G., Zhu W., Chen N., Jin H. Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network. Sci. Rep. 2022;12:1&#x2013;8. doi: 10.1038/s41598-021-03912-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03912-6</ArticleId><ArticleId IdType="pmc">PMC8741798</ArticleId><ArticleId IdType="pubmed">34996987</ArticleId></ArticleIdList></Reference><Reference><Citation>Krystel-Whittemore M., Dileepan K.N., Wood J.G. Mast cell: a multi-functional master cell. Front. Immunol. 2016;6:620. doi: 10.3389/FIMMU.2015.00620/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2015.00620/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC4701915</ArticleId><ArticleId IdType="pubmed">26779180</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman R. da S., Sciences I.S.-M. Connecting the dots in emerging mast cell research: do factors affecting mast cell activation provide a missing link between adverse COVID-19 outcomes and the social determinants of health? Med. Sci. 2022;10:29. doi: 10.3390/medsci10020029. undefined (2022) mdpi.com.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci10020029</ArticleId><ArticleId IdType="pmc">PMC9228930</ArticleId><ArticleId IdType="pubmed">35736349</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria-Castro R., Meneses-Preza Y.G., Rodr&#xed;guez-L&#xf3;pez G.M., Romero-Ram&#xed;rez S., Sosa-Hern&#xe1;ndez V.A., Cervantes-D&#xed;az R., P&#xe9;rez-Fragoso A., Torres-Ru&#xed;z J.J., G&#xf3;mez-Mart&#xed;n D., Campillo-Navarro M., et al. Severe COVID-19 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin. J.&#xa0;Leukoc. Biol. 2021;110:425. doi: 10.1002/JLB.4HI0221-087R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.4HI0221-087R</ArticleId><ArticleId IdType="pmc">PMC8242632</ArticleId><ArticleId IdType="pubmed">34057753</ArticleId></ArticleIdList></Reference><Reference><Citation>Leru P.M. Evaluation and classification of mast cell disorders: a difficult to manage pathology in clinical practice. Cureus. 2022;14:e22177. doi: 10.7759/CUREUS.22177.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/CUREUS.22177</ArticleId><ArticleId IdType="pmc">PMC8841127</ArticleId><ArticleId IdType="pubmed">35174041</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi N., Morovati S., Chan L., Napoleoni C., Mehrani Y., Bridle B.W., Karimi K. Mast cell tryptase and implications for SARS-CoV-2 pathogenesis. BioMed. 2021;1:136&#x2013;149. doi: 10.3390/BIOMED1020013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/BIOMED1020013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pejler G. Novel insight into the in&#xa0;vivo function of mast cell chymase: lessons from knockouts and inhibitors. J.&#xa0;Innate Immun. 2020;12:357&#x2013;372. doi: 10.1159/000506985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000506985</ArticleId><ArticleId IdType="pmc">PMC7506261</ArticleId><ArticleId IdType="pubmed">32498069</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki M., Takai S., Jin D., Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol. Ther. 2006;112:668&#x2013;676. doi: 10.1016/J.PHARMTHERA.2006.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PHARMTHERA.2006.05.008</ArticleId><ArticleId IdType="pubmed">16837049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara M., Urata H., Kinoshita A., Suzumiya J., Sasaguri M., Kikuchi M., Ideishi M., Arakawa K. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension. 1999;33:1399&#x2013;1405. doi: 10.1161/01.HYP.33.6.1399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.33.6.1399</ArticleId><ArticleId IdType="pubmed">10373223</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Wang J., Wang L., Zhan M., Li S., Fang Z., Xu C., Zheng Y., He S. Induction of mast cell accumulation by chymase via an enzymatic activity- and intercellular adhesion molecule-1-dependent mechanism. Br. J. Pharmacol. 2018;175:678. doi: 10.1111/BPH.14117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/BPH.14117</ArticleId><ArticleId IdType="pmc">PMC5786453</ArticleId><ArticleId IdType="pubmed">29197072</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Liu K., Michalicek J., Angus J.A., Hunt J.E., Dell&#x2019;Italia L.J., Feneley M.P., Graham R.M., Husain A. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J.&#xa0;Clin. Invest. 2004;114:112&#x2013;120. doi: 10.1172/JCI20805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI20805</ArticleId><ArticleId IdType="pmc">PMC437969</ArticleId><ArticleId IdType="pubmed">15232618</ArticleId></ArticleIdList></Reference><Reference><Citation>Company C., Piqueras L., Naim Abu Nabah Y., Escudero P., Blanes J.I., Jose P.J., Morcillo E.J., Sanz M.J. Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in&#xa0;vivo. Cardiovasc. Res. 2011;92:48&#x2013;56. doi: 10.1093/CVR/CVR147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CVR/CVR147</ArticleId><ArticleId IdType="pubmed">21622682</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Ramonell R.P., Haddad N.S., Anam F.A., Rudolph M.E., Walker T.A., Truong A.D., Dixit A.N., Han J.E., Cabrera-Mora M., et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature. 2022;611:7934. doi: 10.1038/s41586-022-05273-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammazza A.M., L&#xe9;gar&#xe9; S., Lo Bosco G., Fucarino A., Marino Gammazza A., Giosu&#xe8;, Bosco L., Angileri F., Conway De Macario E., Macario A.J., et al. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19. Cell Stress Chaperones. 2020;25:737&#x2013;741. doi: 10.1007/s12192-020-01148-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-020-01148-3</ArticleId><ArticleId IdType="pmc">PMC7402394</ArticleId><ArticleId IdType="pubmed">32754823</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez-Castilla J., Stebliankin V., Baral P., Balbin C.A., Sobhan M., Cickovski T., Mondal A.M., Narasimhan G., Chapagain P., Mathee K., et al. Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. Viruses. 2022;14:1415. doi: 10.3390/V14071415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/V14071415</ArticleId><ArticleId IdType="pmc">PMC9318917</ArticleId><ArticleId IdType="pubmed">35891400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kova&#x10d;i&#x107; D., Jotanovi&#x107; J., Lakovi&#x107; J. The possible role of molecular mimicry in SARS-CoV-2-mediated autoimmunity: an immunobiochemical basis. J.&#xa0;Med. Sci. 2021;90 doi: 10.20883/MEDICAL.E560.</Citation><ArticleIdList><ArticleId IdType="doi">10.20883/MEDICAL.E560</ArticleId></ArticleIdList></Reference><Reference><Citation>Angileri F., Legare S., Marino Gammazza A., Conway de Macario E., JL Macario A., Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun. Rev. 2020;19 doi: 10.1016/J.AUTREV.2020.102591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AUTREV.2020.102591</ArticleId><ArticleId IdType="pmc">PMC7289093</ArticleId><ArticleId IdType="pubmed">32535095</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D., Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol. Res. 2020;68:310. doi: 10.1007/S12026-020-09152-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S12026-020-09152-6</ArticleId><ArticleId IdType="pmc">PMC7499017</ArticleId><ArticleId IdType="pubmed">32946016</ArticleId></ArticleIdList></Reference><Reference><Citation>Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to &#x201c;potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 2021;224 doi: 10.1016/J.CLIM.2021.108665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CLIM.2021.108665</ArticleId><ArticleId IdType="pmc">PMC7833091</ArticleId><ArticleId IdType="pubmed">33429060</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Yanow S.K., Agrawal B. Editorial: heterologous immunity: implications and applications in vaccines and immunotherapies. Front. Immunol. 2020;11:1408. doi: 10.3389/FIMMU.2020.01408/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2020.01408/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC7381340</ArticleId><ArticleId IdType="pubmed">32774334</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal B. Heterologous immunity: role in natural and vaccine-induced resistance to infections. Front. Immunol. 2019;10:2631. doi: 10.3389/FIMMU.2019.02631/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2019.02631/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC6856678</ArticleId><ArticleId IdType="pubmed">31781118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M., Restrepo-Jim&#xe9;nez P., Monsalve D.M., Pacheco Y., Acosta-Ampudia Y., Ram&#xed;rez-Santana C., Leung P.S.C., Ansari A.A., Gershwin M.E., Anaya J.M. Molecular mimicry and autoimmunity. J.&#xa0;Autoimmun. 2018;95:100&#x2013;123. doi: 10.1016/J.JAUT.2018.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JAUT.2018.10.012</ArticleId><ArticleId IdType="pubmed">30509385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M., Rodr&#xed;guez Y., Acosta-Ampudia Y., Monsalve D.M., Zhu C., Li Q.Z., Ram&#xed;rez-Santana C., Anaya J.M. Autoimmunity is a hallmark of post-COVID syndrome. J.&#xa0;Transl. Med. 2022;20:1&#x2013;5. doi: 10.1186/S12967-022-03328-4/TABLES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S12967-022-03328-4/TABLES/1</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E., Malorni W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur. Respir. J. 2022;59:2102245. doi: 10.1183/13993003.02245-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.F., Yang C. de, Cheng X.B. Anti-interferon autoantibodies in adult-onset immunodeficiency syndrome and severe COVID-19 infection. Front. Immunol. 2021;12:788368. doi: 10.3389/FIMMU.2021.788368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.788368</ArticleId><ArticleId IdType="pmc">PMC8727472</ArticleId><ArticleId IdType="pubmed">35003106</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., B&#xe9;ziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/SCIENCE.ABD4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABD4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S., Nakabo S., Chu J., Hasni S., Kaplan M.J. Association between anti-interferon-alpha autoantibodies and COVID-19 in systemic lupus erythematosus. medRxiv. 2020 doi: 10.1101/2020.10.29.20222000. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.29.20222000</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydon M., Nicaise-Roland P., Mageau A., Farkh C., Daugas E., Descamps V., Dieude P., Dossier A., Goulenok T., Farhi F., et al. Autoantibodies against IFN&#x3b1; in patients with systemic lupus erythematosus and susceptibility for infection: a retrospective case-control study. Sci. Rep. 2022;12 doi: 10.1038/S41598-022-15508-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41598-022-15508-9</ArticleId><ArticleId IdType="pmc">PMC9253327</ArticleId><ArticleId IdType="pubmed">35788140</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbelo P.D., Iadarola M.J., Keller J.M., Warner B.M. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front. Immunol. 2021;12:548469. doi: 10.3389/FIMMU.2021.548469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.548469</ArticleId><ArticleId IdType="pmc">PMC7982651</ArticleId><ArticleId IdType="pubmed">33763057</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J., Lu P., Dhodapkar R.M., Gehlhausen J.R., Tabachnikova A., Tabacof L., Malik A.A., Kamath K., et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv. 2022 doi: 10.1101/2022.08.09.22278592. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese L.H., Winthrop K., Strand V., Yazdany J., Walter J.E. Type I interferon, anti-interferon antibodies, and COVID-19. Lancet Rheumatol. 2021;3:e246&#x2013;e247. doi: 10.1016/S2665-9913(21)00034-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00034-5</ArticleId><ArticleId IdType="pmc">PMC7906736</ArticleId><ArticleId IdType="pubmed">33655222</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., P&#xe9;r&#xe9; H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718. doi: 10.1126/SCIENCE.ABC6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCIENCE.ABC6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Mitchell A., Wang C.Y., Takahashi S., Hoh R., Tai V., Durstenfeld M.S., Hsue P.Y., Kelly J.D., Martin J.N., et al. Low prevalence of interferon-&#x3b1;; autoantibodies in people experiencing long COVID symptoms. J.&#xa0;Infect. Dis. 2022;227:246&#x2013;250. doi: 10.1093/INFDIS/JIAC372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/INFDIS/JIAC372</ArticleId><ArticleId IdType="pmc">PMC9494362</ArticleId><ArticleId IdType="pubmed">36089700</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E., Feng A., Meng W., Apostolidis S.A., Mack E., Artandi M., Barman L., Bennett K., Chakraborty S., Chang I., et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021;12:1&#x2013;15. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., Wong P., et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/S41586-021-03631-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-021-03631-Y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii H., Tsuji T., Yuba T., Tanaka S., Suga Y., Matsuyama A., Omura A., Shiotsu S., Takumi C., Ono S., et al. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : high levels of anti-SSA/Ro antibodies in COVID-19. Clin. Rheumatol. 2020;39:3171&#x2013;3175. doi: 10.1007/S10067-020-05359-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S10067-020-05359-Y</ArticleId><ArticleId IdType="pmc">PMC7447083</ArticleId><ArticleId IdType="pubmed">32844364</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur J.M., Forrest J.C., Boehme K.W., Kennedy J.L., Owens S., Herzog C., Liu J., Harville T.O. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021;16:e0257016. doi: 10.1371/JOURNAL.PONE.0257016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0257016</ArticleId><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeble J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., Muller B., Merle U. Persistent symptoms in adult patients 1 Year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin. Infect. Dis. 2022;74:1191&#x2013;1198. doi: 10.1093/CID/CIAB611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAB611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/J.AUTREV.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.AUTREV.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Estes S.K., Ali R.A., Gandhi A.A., Yalavarthi S., Shi H., Sule G., Gockman K., Madison J.A., Zuo M., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12:eabd3876. doi: 10.1126/SCITRANSLMED.ABD3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCITRANSLMED.ABD3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Low J.G.H., Wong W.H., Chua Y.Y., Goh S.L., Ng H.J. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. Am. J. Hematol. 2020;95:E156. doi: 10.1002/AJH.25822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/AJH.25822</ArticleId><ArticleId IdType="pmc">PMC7262023</ArticleId><ArticleId IdType="pubmed">32267008</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi M.O., Beltagy A., Garrafa E., Curreli D., Cecchini G., Bodio C., Grossi C., Blengino S., Tincani A., Franceschini F., et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front. Immunol. 2020;11:584241. doi: 10.3389/FIMMU.2020.584241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2020.584241</ArticleId><ArticleId IdType="pmc">PMC7593765</ArticleId><ArticleId IdType="pubmed">33178218</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M., Zhang Y., Zhang S., Qin X., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., et al. Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 2020;72:1998&#x2013;2004. doi: 10.1002/ART.41425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.41425</ArticleId><ArticleId IdType="pmc">PMC7361932</ArticleId><ArticleId IdType="pubmed">32602200</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M., Zhang Y., Zhang S., Qin X., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., et al. Brief Report: anti-phospholipid antibodies in critically ill patients with Coronavirus Disease 2019 (COVID-19) Arthritis Rheumatol. 2020;72:1998&#x2013;2004. doi: 10.1002/ART.41425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.41425</ArticleId><ArticleId IdType="pmc">PMC7361932</ArticleId><ArticleId IdType="pubmed">32602200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D., Brodovitch A., Beziane A., Hug S., Bouamri A., Mege J.L., Heim X., Bardin N. Anti-cardiolipin IgG autoantibodies are an independent risk factor of COVID-19 severity. Arthritis Rheumatol. 2020;72:1953&#x2013;1955. doi: 10.1002/ART.41409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ART.41409</ArticleId><ArticleId IdType="pmc">PMC7323091</ArticleId><ArticleId IdType="pubmed">32564467</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavoni V., Gianesello L., Horton A. Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon? J.&#xa0;Thromb. Thrombolysis. 2021;52:542&#x2013;552. doi: 10.1007/S11239-021-02470-Y/TABLES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11239-021-02470-Y/TABLES/1</ArticleId><ArticleId IdType="pmc">PMC8109223</ArticleId><ArticleId IdType="pubmed">33973157</ArticleId></ArticleIdList></Reference><Reference><Citation>Teimury A., Khameneh M.T., Khaledi E.M. Major coagulation disorders and parameters in COVID-19 patients. Eur. J. Med. Res. 2022;27:1&#x2013;10. doi: 10.1186/S40001-022-00655-6/FIGURES/1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S40001-022-00655-6/FIGURES/1</ArticleId><ArticleId IdType="pmc">PMC8845229</ArticleId><ArticleId IdType="pubmed">35168674</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelini D.E., Kaatz S., Rosovsky R.P., Zon R.L., Pillai S., Robertson W.E., Elavalakanar P., Patell R., Khorana A. COVID-19 and venous thromboembolism: a narrative review. Res Pract Thromb Haemost. 2022;6 doi: 10.1002/RTH2.12666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/RTH2.12666</ArticleId><ArticleId IdType="pmc">PMC8847419</ArticleId><ArticleId IdType="pubmed">35224417</ArticleId></ArticleIdList></Reference><Reference><Citation>Giustozzi M., Vedovati M.C., Agnelli G. Venous thromboembolism and COVID-19: mind the gap between clinical epidemiology and patient management. Eur. J. Intern. Med. 2020;82:18. doi: 10.1016/J.EJIM.2020.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJIM.2020.10.018</ArticleId><ArticleId IdType="pmc">PMC7580525</ArticleId><ArticleId IdType="pubmed">33127217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yu C., Jing H., Wu X., Novakovic V.A., Xie R., Shi J. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front. Cell. Infect. Microbiol. 2022;12:861703. doi: 10.3389/FCIMB.2022.861703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCIMB.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonello M., Mattia E., Favaro M., Del Ross T., Calligaro A., Salvan E., Hoxha A., Fedrigo M., Ruffatti A. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thromb. Res. 2019;177:157&#x2013;160. doi: 10.1016/J.THROMRES.2019.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.THROMRES.2019.03.006</ArticleId><ArticleId IdType="pubmed">30903876</ArticleId></ArticleIdList></Reference><Reference><Citation>Preti P.S., Russo M., Caneva L., Reduzzi M., Calabretta F., Spataro C., Grimaldi P., De Amici M., Testa G., Iotti G.A., et al. Increased prevalence of heparin induced thrombocytopenia in COVID-19 patients. Thromb. Res. 2021;203:33. doi: 10.1016/J.THROMRES.2021.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.THROMRES.2021.04.016</ArticleId><ArticleId IdType="pmc">PMC8054612</ArticleId><ArticleId IdType="pubmed">33915353</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zhang X., Xiao Y., Gao T., Wang G., Wang Z., Zhang Z., Hu Y., Dong Q., Zhao S., et al. Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment. medRxiv. 2020 doi: 10.1101/2020.04.23.20076851. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.23.20076851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly J., Haupt L., Joubert J., Loebenberg P., Jacobson B.F., Louw V.J., Wessels P.F., Opie J.J. Heparin-induced thrombocytopenia: an update for the COVID-19 era. S.&#xa0;Afr. Med. J. 2021;111:841&#x2013;848. doi: 10.7196/SAMJ.2021.V111I9.15909.</Citation><ArticleIdList><ArticleId IdType="doi">10.7196/SAMJ.2021.V111I9.15909</ArticleId><ArticleId IdType="pubmed">34949247</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrhofer J., Graninger M., Lettenmaier L., Schweighardt J., Gentile S.A., Koidl L., Ret D., Stingl M., Puchhammer-St&#xf6;ckl E., Untersmayr E. Association between Epstein-barr-virus reactivation and development of long-COVID fatigue. Allergy. 2023;78:297&#x2013;299. doi: 10.1111/ALL.15471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ALL.15471</ArticleId><ArticleId IdType="pmc">PMC9538037</ArticleId><ArticleId IdType="pubmed">35950630</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolou E., Rizwan M., Moustardas P., Sj&#xf6;gren P., Bertilson B.C., Brag&#xe9;e B., Polo O., Ros&#xe9;n A. Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. Front. Immunol. 2022;13:6407. doi: 10.3389/FIMMU.2022.949787/BIBTEX.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2022.949787/BIBTEX</ArticleId><ArticleId IdType="pmc">PMC9630598</ArticleId><ArticleId IdType="pubmed">36341457</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnieri J.W., Dybas J.M., Fazelinia H., Kim M.S., Frere J., Zhang Y., Albrecht Y.S., Murdock D.G., Angelin A., Singh L.N., et al. Targeted down regulation of core mitochondrial genes during SARS-CoV-2 infection. bioRxiv. 2022 doi: 10.1101/2022.02.19.481089. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.19.481089</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E., Wist J., Masuda R., Lodge S., Nitschke P., Kimhofer T., Loo R.L., Begum S., Boughton B., Yang R., et al. Incomplete systemic recovery and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 patients: implications for assessment of post-acute COVID-19 syndrome. J.&#xa0;Proteome Res. 2021;20:3315&#x2013;3329. doi: 10.1021/ACS.JPROTEOME.1C00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ACS.JPROTEOME.1C00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajaz S., McPhail M.J., Singh K.K., Mujib S., Trovato F.M., Napoli S., Agarwal K. Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. Am. J. Physiol. Cell Physiol. 2021;320:C57&#x2013;C65. doi: 10.1152/AJPCELL.00426.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/AJPCELL.00426.2020</ArticleId><ArticleId IdType="pmc">PMC7816428</ArticleId><ArticleId IdType="pubmed">33151090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E., Hall K.H., Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 &#x201c;long-haulers&#x201d;. Chronic Dis Transl Med. 2021;7:14&#x2013;26. doi: 10.1016/J.CDTM.2020.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CDTM.2020.11.002</ArticleId><ArticleId IdType="pmc">PMC7680046</ArticleId><ArticleId IdType="pubmed">33251031</ArticleId></ArticleIdList></Reference><Reference><Citation>Allali I., Bakri Y., Amzazi S., Ghazal H. Gut-lung Axis in COVID-19. Interdiscip Perspect Infect Dis. 2021;2021:6655380. doi: 10.1155/2021/6655380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6655380</ArticleId><ArticleId IdType="pmc">PMC7979298</ArticleId><ArticleId IdType="pubmed">33777139</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannos P., Prokopidis K. Gut dysbiosis and long COVID-19: feeling gutted. J.&#xa0;Med. Virol. 2022;94:2917. doi: 10.1002/JMV.27684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JMV.27684</ArticleId><ArticleId IdType="pmc">PMC9088471</ArticleId><ArticleId IdType="pubmed">35233795</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Q., Lau R.I., Liu Q., Chan F.K.L., Ng S.C. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2022;72:1230&#x2013;1232. doi: 10.1136/GUTJNL-2022-328319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/GUTJNL-2022-328319</ArticleId><ArticleId IdType="pubmed">35940857</ArticleId></ArticleIdList></Reference><Reference><Citation>Haran J.P., Bradley E., Zeamer A.L., Cincotta L., Salive M.C., Dutta P., Mutaawe S., Anya O., Meza-Segura M., Moormann A.M., et al. Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight. 2021;6:e152346. doi: 10.1172/JCI.INSIGHT.152346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI.INSIGHT.152346</ArticleId><ArticleId IdType="pmc">PMC8564890</ArticleId><ArticleId IdType="pubmed">34403368</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2021;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighauser M., Arseni D., Bacioglu M., Huang M., L&#xf6;vestam S., Shi Y., Yang Y., Zhang W., Kotecha A., Garringer H.J., et al. Age-dependent formation of TMEM106B amyloid filaments in human brains. Nature. 2022;605:310&#x2013;314. doi: 10.1038/S41586-022-04650-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41586-022-04650-Z</ArticleId><ArticleId IdType="pmc">PMC9095482</ArticleId><ArticleId IdType="pubmed">35344985</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S., Hammarstr&#xf6;m P. Amyloidogenesis of SARS-CoV-2 spike protein. J.&#xa0;Am. Chem. Soc. 2022;144:8945&#x2013;8950. doi: 10.1021/JACS.2C03925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/JACS.2C03925</ArticleId><ArticleId IdType="pmc">PMC9136918</ArticleId><ArticleId IdType="pubmed">35579205</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavi L. Postural tachycardia syndrome and long COVID: an update. Br. J. Gen. Pract. 2022;72:8&#x2013;9. doi: 10.3399/BJGP22X718037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/BJGP22X718037</ArticleId><ArticleId IdType="pmc">PMC8714530</ArticleId><ArticleId IdType="pubmed">34972793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadda K.R., Blakey E.E., Huang C.L.H., Jeevaratnam K. Long COVID-19 and postural orthostatic tachycardia SyndromeIs dysautonomia to Be blamed? Front Cardiovasc Med. 2022;9:860198. doi: 10.3389/FCVM.2022.860198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCVM.2022.860198</ArticleId><ArticleId IdType="pmc">PMC8959615</ArticleId><ArticleId IdType="pubmed">35355961</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M., Dirksen A., Taraborrelli P., Torocastro M., Panagopoulos D., Sutton R., Lim P.B. Autonomic dysfunction in &#x2018;long COVID&#x2019;: rationale, physiology and management strategies. Clin. Med. 2021;21:e63. doi: 10.7861/CLINMED.2020-0896.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/CLINMED.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkai I., Mayer M.G., Hellmers L.M., Ning B., Huang Z., Monjure C.J., Coyne C., Silvestri R., Golden N., Hensley K., et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat. Commun. 2022;13:1&#x2013;13. doi: 10.1038/s41467-022-29440-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29440-z</ArticleId><ArticleId IdType="pmc">PMC8975902</ArticleId><ArticleId IdType="pubmed">35365631</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>